Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CEO Eric M. Dube sold 50,691 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.21, for a total value of $1,024,465.11. Following the completion of the transaction, the chief executive officer now directly owns 430,548 shares of the company’s stock, valued at approximately $8,701,375.08. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Travere Therapeutics Price Performance
Shares of NASDAQ:TVTX opened at $21.10 on Wednesday. The business has a 50-day moving average of $18.69 and a two-hundred day moving average of $15.47. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.56.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on TVTX. Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating for the company. Leerink Partners reissued an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Wedbush upped their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. HC Wainwright lifted their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Finally, Guggenheim increased their price target on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.
Institutional Trading of Travere Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in shares of Travere Therapeutics in the fourth quarter worth about $53,000. CWM LLC lifted its position in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares in the last quarter. Quarry LP purchased a new position in Travere Therapeutics in the 3rd quarter worth approximately $105,000. Sei Investments Co. acquired a new stake in Travere Therapeutics in the second quarter valued at approximately $117,000. Finally, Diversified Trust Co purchased a new stake in shares of Travere Therapeutics during the third quarter valued at approximately $161,000.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading
- Five stocks we like better than Travere Therapeutics
- Manufacturing Stocks Investing
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.